REG - Feedback PLC - Change of Adviser

FeedbackAnnouncement

25/08/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210825:nRSY6679Ja&default-theme=true

RNS Number : 6679J  Feedback PLC  25 August 2021

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of
this announcement, this information is now considered to be in the public
domain.

 

Feedback plc

 

Change of Nominated Adviser and Broker

 

London, 25 August 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"),
the specialist medical imaging technology and secure clinical communications
company, is pleased to announce Panmure Gordon (UK) Limited has been appointed
as the Company's Nominated Adviser and Sole Broker with immediate effect.

 

Dr Tom Oakley, CEO of Feedback, said: "In line with our strategy to drive
clinical adoption of Bleepa both here in the UK and internationally, we are
delighted to be working with Panmure Gordon, whose appointment, as industry
specialists, signals a step change in our growth plans.  We believe that
their deep understanding of the sector, networks and broad institutional
reach, will help us to progress our vision to enable clinicians to better
securely communicate using everyday mobile technology, no matter their own
location."

 

 

 

 

-Ends-

 

Enquiries:

 

 Feedback plc                                    +44 (0)1954 718072

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Lindsay Melvin, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson         07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business with a
secure clinical communications platform. Its core product, Bleepa, is a
revolutionary medical imaging communications app, providing an easy-to-use,
high quality tool to enable remote and secure communications between
front-line clinicians and teams. Importantly, it is the only CE marked medical
imaging communications platform on the NHSx clinical communications tools
framework. Bleepa has unparalleled functionality for everyday practice and can
be accessed from any internet-connected device, enabling control of patient
cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will
provide increasing levels of visibility as the Company grows its customer
base. With a growing distribution base and technology in place, the focus is
on leveraging key relationships in order to drive sales both in the UK and
internationally to all forms of care providers. As a fully certified medical
device, Bleepa aims to disrupt the medical imaging communications market and,
importantly, increase the accuracy and speed of clinical review.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPEAEPLAEPFEAA